Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer
- 1 February 2015
- journal article
- Published by Elsevier in Human Pathology
- Vol. 46 (2) , 182-190
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Cancer Epidemiology, Biomarkers & Prevention, 2012
- Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older ageBreast Cancer Research and Treatment, 2010
- Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation CarriersJournal of Clinical Oncology, 2009
- Prognosis of BRCA-associated breast cancer: a summary of evidenceBreast Cancer Research and Treatment, 2009
- Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer casesEuropean Journal of Cancer, 2007
- Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic PredispositionNew England Journal of Medicine, 2004
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi JewsNew England Journal of Medicine, 1997
- Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic casesThe Lancet, 1997